by Jim Reddoch
The stock market has had a rough year, but the performance of the Nasdaq — down 15 percent — is downright enviable for biotech investors. The BTK stock average is down 28 percent for 2002 to date. Genomics stocks have largely tracked the BTK in ’02, but underperformed in 2001.
This column takes on the idea of “trough valuations,” or in other words, how low can they go?